Medtronic PLC (NYSE:MDT) EVP Geoffrey Martha sold 11,000 shares of the firm’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $96.05, for a total value of $1,056,550.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
NYSE:MDT opened at $97.39 on Friday. The company has a market capitalization of $130.62 billion, a price-to-earnings ratio of 18.66, a price-to-earnings-growth ratio of 2.50 and a beta of 0.68. Medtronic PLC has a 52-week low of $81.66 and a 52-week high of $100.15. The company’s fifty day simple moving average is $93.94. The company has a quick ratio of 2.15, a current ratio of 2.59 and a debt-to-equity ratio of 0.49.
Medtronic (NYSE:MDT) last posted its quarterly earnings data on Thursday, May 23rd. The medical technology company reported $1.54 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.47 by $0.07. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.12 billion. Medtronic had a return on equity of 14.16% and a net margin of 15.15%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the company earned $1.42 earnings per share. On average, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. Cordasco Financial Network bought a new stake in Medtronic during the first quarter worth about $27,000. Pin Oak Investment Advisors Inc. lifted its stake in Medtronic by 158.0% during the fourth quarter. Pin Oak Investment Advisors Inc. now owns 369 shares of the medical technology company’s stock worth $34,000 after purchasing an additional 226 shares during the last quarter. Spectrum Management Group Inc. lifted its stake in Medtronic by 353.8% during the first quarter. Spectrum Management Group Inc. now owns 413 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 322 shares during the last quarter. Mackey Komara & Dankovich LLC bought a new stake in Medtronic during the first quarter worth about $38,000. Finally, Capital Financial Planning LLC bought a new stake in Medtronic during the fourth quarter worth about $42,000. 80.03% of the stock is owned by institutional investors.
MDT has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $121.00 target price on shares of Medtronic in a research report on Monday, May 27th. UBS Group raised their target price on Medtronic to $112.00 and gave the stock a “buy” rating in a research report on Friday, June 14th. Northland Securities reissued a “hold” rating and issued a $100.00 target price on shares of Medtronic in a research report on Thursday, June 20th. Zacks Investment Research upgraded Medtronic from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Finally, Wells Fargo & Co reduced their price target on Medtronic from $101.00 to $100.00 and set a “market perform” rating for the company in a research report on Thursday, April 4th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $105.48.
Medtronic Company Profile
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Read More: What does an outperform rating mean?
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.